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Abstract
Background: Celastrol, an active compound extracted from the root of the Chinese medicine ‘‘Thunder of God Vine’’
(Tripterygium wilfordii), exhibits anticancer, antioxidant and anti-inflammatory activities, and interest in the therapeutic
potential of celastrol is increasing. However, described side effects following treatment are significant and require
investigation prior to initiating clinical trials. Here, we investigated the effects of celastrol on the adult murine
hematopoietic system.
Methodology/Principal Findings: Animals were treated daily with celastrol over a four-day period and peripheral blood,
bone marrow, spleen, and peritoneal cavity were harvested for cell phenotyping. Treated mice showed specific impairment
of the development of B cells and erythrocytes in all tested organs. In bone marrow, these alterations were accompanied by
decreases in populations of common lymphoid progenitors (CLP), common myeloid progenitors (CMP) and megakaryocyte-
erythrocyte progenitors (MEP).
Conclusions/Significance: These results indicate that celastrol acts through regulators of adult hematopoiesis and could be
used as a modulator of the hematopoietic system. These observations provide valuable information for further assessment
prior to clinical trials.
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Introduction
Tripterygium wilfordii, an ivy-like vine also known as the ‘‘Thunder
God Vine’’, has been used as natural medicine in China for
hundreds of years [1]. Celastrol, a quinone methide triterpenoid,
was identified to be one of its active components. As root extract or
purified compound, its remarkable anti-inflammatory ability has
been demonstrated in animal models of different inflammatory
diseases including asthma [2], Crohn’s disease [3], and neurode-
generative disorders [4,5]. Purified celastrol showed anticancer
activity, in vivo in various tumor models of melanoma [6], prostate
[7] and breast [8] cancer, as well as in vitro on leukemic cell lines
[9,10,11], suggesting its use as a cancer therapeutic.
However, multiple side effects have been reported, including
leukopenia, thrombocytopenia and anemia [12]. These adverse
reactions are transient and recovery is usually complete upon
removal of the drug. The molecular bases of the therapeutic and
side effects are not well understood. Therefore, to advance
celastrol as a therapeutic and prevent side effects, its toxicity and
mechanism of action need to be revealed.
In the present study, we investigated the effects of celastrol on
the hematopoietic system of adult mice with the aim of describing
the immediate effects of celastrol on different mature and
progenitor hematopoietic cell populations. We observed significant
alterations of stem cells, progenitors and fully differentiated cell
populations in peripheral blood (PB), bone marrow (BM), spleen
and peritoneal cavity (PerC). These data indicate significant
hematotoxicity, and suggest differential effects of celastrol on
specific hematopoietic subsets. Understanding these effects will
better enable the use of this potential therapeutic agent and will
identify new clinical applications.
Materials and Methods
1- Mice and chemical treatment
BALB/c mice, 8- to 10-weeks-old, were purchased from
Jackson Labs. All mice were maintained in the Animal Facility at
Stanford University School of Medicine. All experiments were
conducted under strict adherence to institutional guidelines, as
approved by the Animal Care and Use Committee at Stanford
University (aplac #12323). Mice received daily intraperitoneal
(IP) injections (200 mL) of either celastrol (Cayman Chemical,
purity $ 98%) diluted solutions (0.01, 0.1, 1 or 5 mg/kg/day), or
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of four days.
2- Tissue preparation and flow cytometry
Tissues were harvested the day following the last injection as
previously described [13]. Cells were counted and stained with
antibodies for phenotyping. For mature population analyses, cell
suspensions were preincubated with anti–CD16/CD32 mAb to
block FccRII/III receptors and stained with the following
fluorochrome-conjugated mAb: FITC-labeled anti-CD71; PE-
labeled anti–Ter119, PECy5-labeled anti-CD5; PECy5.5-labeled
anti-CD19; PECy7-labeled anti–IgM; APCCy5.5-labeled anti-
IgD; APCCy7-labeled anti-CD11b and Pacific Blue–labeled anti–
Gr-1, and Violet Green-labeled LIVE/DEADH. For progenitors
analyses, cells were stained with FITC-labeled anti-CD34, PE-
labeled anti–Sca1, APC-labeled anti-c-Kit, PECy7-labeled anti-
Il7Ra, APCCy7-labeled anti-CD16/32 and PerCPCy5.5-labeled
lineage antibody cocktail. Antibodies were either purchased
(Invitrogen and BD) or conjugated in the Herzenberg laboratory.
Cells were analyzed on LSRII (BD). Data were analyzed with
FlowJo software (TreeStar). In the carrier only treated-animals
(PBS with 5% DMSO) there were no detectable changes in the
levels of CD expression.
3- Statistical analyses
Quantitative data are expressed as the mean 6 SEM. Statistical
significance was assayed using a non-parametric Mann Whitney
test (n=10 mice. *p,0.05; **p,0.01; ***p,0.001).
Results and Discussion
1- Changes in peripheral blood parameters in celastrol
treated-mice
To investigate the effects of celastrol on the hematopoietic
system, mice received daily IP injections (0.01, 0.1, 1 or 5 mg/kg/
day) over the course of 4 days, and tissues were harvested the day
Figure 1. Changes in peripheral blood parameters and cellularity in celastrol treated-BALB/c mice. (A) Peripheral blood parameters in
celastrol treated-mice. Mice received four consecutive daily IP injections of DMSO 5% or various concentrations of celastrol (0.01, 0.1, 1 or 5 mg/kg/
day). Peripheral blood was harvested the day following the last injection. Values are percent of control. RBC: red blood cells; HGB: Hemoglobin; HCT:
hematocrit; WBC: white blood cells. Mean 6 SEM, n=10. (B) Cellularity in control and celastrol treated-mice. Mice received four consecutive daily IP
injections of DMSO 5% or celastrol (5 mg/kg). Cells from bone marrow (1 femur+1 tibia), spleen and peritoneal cavity were harvested the day
following the last injection. Mean 6 SEM, n=10.
doi:10.1371/journal.pone.0035733.g001
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of red blood cells and similar levels of hemoglobin and hematocrit
in mice treated at all concentrations of celastrol, compared with
control mice treated with 5% DMSO (Figure 1A). Mice treated
with the highest concentration of celastrol showed signs of toxicity
with hunched posture and ruffled fur. These mice appeared to
have more total white blood cells than did control mice, although
it was not statistically significant (n=10; p.0.05) (Figure 1A). This
data indicated that we should further analyze mice treated with
celastrol at 5 mg/kg/day.
2- Celastrol treatment results in multiple defects in
mature lineages
We then examined the distribution of the different PB
hematopoietic lineages using flow cytometric analysis and
specific cell surface markers. The percentages shown correspond
to raw data numbers. FACS analysis revealed dramatic
alterations in the lymphoid, myeloid and erythroid populations
following celastrol treatment (Figure 2A), in agreement with
previous studies describing aplastic anemia in patients treated
with extracts of T. wilfordii [14], and blood defects in zebrafish
embryos exposed to pure celastrol [15]. Lymphoid markers
indicated that blood from celastrol treated-mice contained fewer
total T lymphocytes (CD5
+) (2.8-fold; *p,0.05) with no apparent
change in the total B lymphocyte population (CD19
+).
Interestingly, celastrol induced a significant decrease in the
number of immature B and B-1 cells (6.7-fold; ***p,0.001) with
a modest increase in the mature B cell population (1.2-fold;
**p,0.01) (Figure 2A). Among the remaining ‘‘non-T’’ and
‘‘non-B’’ PB cells, the cell size combined with staining for Gr-1
and CD11b myeloid markers indicated a significant increase of
the neutrophils (5.2-fold; ***p,0.001) and a slight increase of the
eosinophils (1.7-fold; **p,0.01) (Figure 2A). This may be a
consequence of an inhibition of the infiltration of inflammatory
cells into tissues since celastrol has been previously shown to
reduce the total number of inflammatory cells in peribronchial
areas in a mouse asthma model [2]. The immature red cells,
identified by the staining intensities of anti-Ter119 and -CD71
surface markers, were present but at an extremely low level
(Figure 2A). These effects were transient, as recovery was
complete four weeks after removal of the drug (data not shown).
The alterations affecting the development of B cells and
erythrocytes were also found in BM as well as in spleen and PerC
(Figure 2B and 2C). In the PerC, the B-1 population [13] was
highly affected (13.5-fold decrease; ***p,0.001) (Figure 2B).
Celastrol did not appear to be directly cytotoxic in our study,
as we did not observe decreases in the cellularity in any of the
tested organs (Figure 1B). This is in agreement with a study
describing no decrease in cell viability and no evidence of
increased apoptosis of CD34
+ human BM cells treated with
extract of T. wilfordii [16]. Moreover, using colony-forming cell
assays, it was demonstrated that the extracted compound directly
blocks the ability of very early human hematopoietic multi-
lineage, as well as lineage-specific committed, human hemato-
poietic progenitor cell to respond to growth factors and form
colonies [16]. Thus we anticipate that the erythrocytic and B-
lymphoblastic suppression described in our present study may be
Figure 2. Celastrol treatment results in multiple defects in mature lineages. (A) Representative FACS analysis of mature lineages from
peripheral blood of control (left) and celastrol treated-mice (right). Mice received four consecutive daily intraperitoneal injections and peripheral
blood cells were harvested the day following the last injection, processed and analyzed as described in Materials and Methods. The percentages
shown correspond to raw data numbers. Data shown are representative of 10 mice. (B) Representative FACS analysis of total B cells (gated as LIVE/
DEAD
+, CD5
2, CD19
+, and analyzed for IgD and IgM expression) from bone marrow, spleen and peritoneal cavity of control (left) and celastrol
treated-mice (right) (n=10). FACS-analysis of the different sub-populations of B lymphoid progenitors was performed as described [13,20]. MZ B cells:
Marginal Zone B cells. (C) Representative FACS analysis of total red cells (gated as LIVE/DEAD
+, CD5
2, CD19
2, CD11b
2, Gr-1
2, SSC-A
low and analyzed
for CD71 and Ter119 expressions) from bone marrow, spleen and peritoneal cavity of control (left) and celastrol treated-mice (right) (n=10). FACS-
analysis of the different sub-populations of red cell progenitors was performed as described [21,22].
doi:10.1371/journal.pone.0035733.g002
Figure 3. Celastrol treatment results in multiple defects in BM progenitors. Representative FACS analysis of Megakaryocyte-Erythrocyte
Progenitors (MEP), Common Myeloid Progenitors (CMP), Granulocyte-Monocyte Progenitors (GMP), LSK CD34
2 (Lin
2 Sca-1
+ c-Kit
+ CD34
2) cells and
Common Lymphoid Progenitors (CLP) from bone marrow of control (left) and celastrol treated-mice (right) (n=10). Cells were harvested from animals
treated as described in Figure 2 and percentages shown correspond to raw data numbers. FACS-analysis of the different sub-populations of
multipotent progenitors was performed as described [23].
doi:10.1371/journal.pone.0035733.g003
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pluripotent cells exposed to celastrol.
3- Celastrol treatment results in multiple defects in bone
marrow progenitors
Therefore, we examined the distribution of the different
progenitors in the BM from celastrol treated-mice (Figure 3). We
observed a 1.3-fold increase in the number of LSK CD34
2 cells
(Lin
2 Sca1
+ c-Kit
+ CD34
2), when compared to control mice
(**p,0.01). We also showed decreases in the number of Common
Myeloid Progenitors (CMPs) (2-fold; **p,0.01) and Megakaryo-
cyte-Erythrocyte Progenitors (MEPs) (1.7-fold; **p,0.01), whereas
the number of Granulocyte-Monocyte Progenitors (GMPs)
increased (1.8-fold; **p,0.01). This suggests a potential priming
of celastrol-treated CMPs towards GMPs. Finally, the number of
Common Lymphoid Progenitors (CLPs) was significanly decreased
(17-fold; ***p,0.001) after celastrol treatment.
These results show that celastrol specifically impairs the
development of B cells and erythrocytes in PB, BM, spleen and
PerC. Thus, a potential use of the drug could be to modulate the
hematopoietic cell subsets, by treating cells ex vivo prior to
adoptive transfer, or by treating donors prior to collection and
purification of cells. Additional studies are needed to determine the
kinetics of these effects, and to identify the proper dose of celastrol
for each type of cell to be modulated.
The molecular mechanism underlying the effects of celastrol on
the hematopoietic system is not well understood. One explanation
may be the inhibition of Nuclear Factor-kappa B (NF-kB)
pathways by celastrol [2]. A complete understanding of NF-kB
signaling in erythropoiesis is not completely defined, but a role for
NF-kB family members, including p105/p50, p100/p52 and p65,
has been suggested [17,18]. Moreover, genetic studies show that
the different NF-kB proteins are important at different stages of B
cell maturation [19]. Inhibition of NF-kB is a strategy that has
great potential as a drug target in the treatment of various
inflammatory diseases and cancer. Use of celastrol as a single agent
or in combination with existing therapies for inhibition of NF-kB,
may be an effective strategy. The multifaceted effects of celastrol
on the hematopoietic system suggest that there may be several
molecular targets, and this will need to be resolved for a more
complete understanding of both the desired, and the adverse,
effects of celastrol as a potential therapeutic agent. It is now
apparent that the adverse effects of celastrol on the hematopoietic
system need to be thoroughly evaluated prior to the initiation of
further clinical studies.
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